Company intelligence / Profile preview

Endonovo Therapeutics

Woodland Hills, California, United Statesendonovo.com ↗

Ownership: Public · ENDV
Employees: ~25
Development stage: Commercial

Overview

Endonovo’s FDA-cleared Electroceutical Therapy is indicated for palliative treatment of pain and post-surgical edema, and is CE Marked for wound healing. Its pipeline targets cardiovascular and central nervous system disorders, with ongoing clinical development in areas like traumatic brain injury and multiple sclerosis[2][3][4][5].

Therapeutic areas: DermatologyImmunologyNeurologyOtherCardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

SofPulse

Commercial

Indications: Post-surgical pain, Post-surgical edema, Chronic wounds

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $31.9K
Total revenue: $0
Enterprise value: $7M

Beyond the preview

Go deeper on Endonovo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endonovo Therapeutics.

Explore the full profile